Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism

References

• Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.
   PubMed Web of Science ®Google Scholar
• Moayeri A, Mohamadpour M, Mousavi SF, et al. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017;13:455–468.
   PubMed Web of Science ®Google Scholar
• Asokan AG, Jaganathan J, Philip R, et al. Evaluation of bone mineral density among type 2 diabetes mellitus patients in South Karnataka. J Nat Sci Biol Med. 2017;8(1):94–98.
   PubMedGoogle Scholar
• Hamann C, Kirschner S, Günther K-P, et al. Bone, sweet bone—osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol. 2012;8(5):297–305.
   PubMed Web of Science ®Google Scholar
• Thrailkill KM, Lumpkin CK Jr, Bunn RC, et al. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735–E745.
   PubMed Web of Science ®Google Scholar
• Brown SA, Sharpless JL. Osteoporosis: an under-appreciated complication of diabetes. Clin Diabetes. 2004;22(1):10–20.
   Google Scholar
• Wientroub S, Eisenberg D, Tardiman R, et al. Is diabetic osteoporosis due to microangiopathy? Lancet. 1980;2(8201):983.
   PubMed Web of Science ®Google Scholar
• Vogt MT, Cauley JA, Kuller LH, et al. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res. 1997;12(2):283–289.
   PubMed Web of Science ®Google Scholar
• Jackuliak P, Payer J. Osteoporosis, fractures, and diabetes. Int J Endocrinol. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Hygum K, Starup-Linde J, Langdahl BL. Diabetes and bone. Osteoporos Sarcopenia. 2019;5(2):29–37.
   PubMedGoogle Scholar
• Paschou SA, Dede AD, Anagnostis PG, et al. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab. 2017;102(10):3621–3634.
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Leslie WD, Lix LM, et al. Longer duration of diabetes strongly impacts fracture risk assessment: the Manitoba BMD cohort. J Clin Endocrinol Metab. 2016;101(11):4489–4496.
   PubMed Web of Science ®Google Scholar
• Mirza F, Canalis E. Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131–R151.
   PubMed Web of Science ®Google Scholar
• Tuck S, Francis R. Testosterone, bone and osteoporosis. Front Horm Res. 2009;37:123–132.
   PubMed Web of Science ®Google Scholar
• Morton A. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2005;90(3):1903.
   PubMed Web of Science ®Google Scholar
• Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. Diabetes care in the hospital: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S244–S253.
   PubMedGoogle Scholar
• Francomano D, Bruzziches R, Barbaro G, et al. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest. 2014;37(4):401–411.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Dandona P. Letter to editor: long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels. J Clin Endocrinol Metab. 2018;103(5):2069–2070.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Alwani M, Talib R, et al. Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. Aging Male. 2020;23(5):1553–1563.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as a marker of impaired vascular integrity in middle-aged overweight men. J Mens Health. 2009;6(3):243.
   Web of Science ®Google Scholar
• Haider A, Saad F, Doros G, et al. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract. 2014;8(4):e339–e349.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Alwani M, et al. The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study. Aging Male. 2022;25(1):185–191.
   PubMed Web of Science ®Google Scholar
• Khripun I, Vorobyev S, Belousov I, et al. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male. 2019;22(4):241–249.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male. 2008;11(3):107–117.
   PubMed Web of Science ®Google Scholar
• Golds G, Houdek D, Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017;2017:4602129.
   PubMed Web of Science ®Google Scholar
• Delmas PD. What do we know about biochemical bone markers? Baillieres Clin Obstet Gynaecol. 1991;5(4):817–830.
   PubMedGoogle Scholar
• Hygum K, Starup-Linde J, Harsløf T, et al. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover – a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(3):R137–R157.
   PubMed Web of Science ®Google Scholar
• Kim HS, Jeong ES, Yang MH, et al. Bone mineral density assessment for research purpose using dual energy X-ray absorptiometry. Osteoporos Sarcopenia. 2018;4(3):79–85.
   PubMedGoogle Scholar
• Haseltine KN, Chukir T, Smith PJ, et al. Bone mineral density: clinical relevance and quantitative assessment. J Nucl Med. 2021;62(4):446–454.
   PubMed Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21(3):158–169.
   PubMed Web of Science ®Google Scholar
• Groti Antonič K, Antonič B, Žuran I, et al. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male. 2020;23(5):1442–1454.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
   PubMed Web of Science ®Google Scholar
• Wu FCW, Tajar A, Beynon JM, et al.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020;8(5):970–987.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021;24(1):119–138.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Zitzmann M, Traish AM, et al. International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. Aging Male. 2015;18(4):205–206.
   PubMed Web of Science ®Google Scholar
• Free & bioavailable testosterone calculator [Internet]. [cited 2022]. Available from: http://www.issam.ch/freetesto.htm.
   Google Scholar
• Groti Antonič K, Antonič B, Pfeifer M. Effects of testosterone therapy on erythrocytosis and prostate adverse events in obese males with functional hypogonadism and type 2 diabetes in a 2-year clinical trial. Androg Clin Res Ther. 2020;1(1):85–93.
   Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol. 2001;54(6):739–750.
   PubMed Web of Science ®Google Scholar
• Guo CY, Jones TH, Eastell R. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab. 1997;82(2):658–665.
   PubMed Web of Science ®Google Scholar
• Ng Tang Fui M, Hoermann R, Nolan B, et al. Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial. Sci Rep. 2018;8(1):9099.
   PubMedGoogle Scholar
• Ng Tang Fui M, Hoermann R, Bracken K, et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT. J Clin Endocrinol Metab. 2021;106(8):e3143–e3158.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966–1972.
   PubMed Web of Science ®Google Scholar
• Behre HM, Tammela TLJ, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15:198–207.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tolrà J, Torremadé J, di Gregorio S, et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology. 2013;1(4):570–575.
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471–479.
   PubMed Web of Science ®Google Scholar
• Haider A, Meergans U, Traish A, et al. Progressive improvement of T-scores in men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int J Endocrinol. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89(2):503–510.
   PubMed Web of Science ®Google Scholar
• Saad F, Doros G, Haider KS, et al. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. Int J Obes. 2020;44(6):1264–1278.
   Web of Science ®Google Scholar
• Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91(6):2011–2016.
   PubMed Web of Science ®Google Scholar
• Wolf J, Keipert D, Motazedi H, et al. Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study. Aging Male. 2017;20(4):225–234.
   PubMed Web of Science ®Google Scholar
• Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol. 2009;5(8):437–443.
   PubMed Web of Science ®Google Scholar
• Vandewalle S, Taes Y, Fiers T, et al. Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents. J Clin Endocrinol Metab. 2014;99(7):E1272–E1282.
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton I, Atkinson E, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83(7):2266–2274.
   PubMed Web of Science ®Google Scholar
• Movérare S, Venken K, Eriksson A-L, et al. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci U S A. 2003;100(23):13573–13578.
   PubMed Web of Science ®Google Scholar
• Nguyen HTT, von Schoultz B, Nguyen TV, et al. Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men. J Bone Miner Metab. 2015;33(6):658–665.
   PubMed Web of Science ®Google Scholar
• Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology. 1989;124(3):1576–1578.
   PubMed Web of Science ®Google Scholar
• Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res. 2002;57:385–409.
   PubMedGoogle Scholar
• Michael H, Härkönen PL, Väänänen HK, et al. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20(12):2224–2232.
   PubMed Web of Science ®Google Scholar
• Martín-Fernández M, Garzón-Márquez F-M, Díaz-Curiel M, et al. Comparative study of the effects of osteoprotegerin and testosterone on bone quality in male orchidectomised rats. Aging Male. 2020;23(3):189–201.
   PubMed Web of Science ®Google Scholar
• Wong SK, Mohamad N-V, Jayusman PA, et al. The use of selective estrogen receptor modulators on bone health in men. Aging Male. 2019;22(2):89–101.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Huang G, Basaria S, et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414–424.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes. Clin Endocrinol. 2016;85(5):772–780.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Cremers JF, Krallmann C, et al. The HEAT-Registry (HEmatopoietic affection by testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men. Aging Male. 2022;25(1):134–144.
   PubMed Web of Science ®Google Scholar